Do small interfering RNA (siRNA) therapies reduce triglycerides and improve lipid profiles in patients with hypertriglyceridemia and mixed dyslipidemia?
siRNA therapies targeting APOC3 and ANGPTL3 are effective and safe for reducing triglycerides and modulating broader lipid profiles in patients with hypertriglyceridemia and mixed dyslipidemia.
siRNA therapies demonstrate significant efficacy in reducing triglycerides and improving lipid profiles in patients with HTG and mixed dyslipidemia. APOC3-targeted treatments primarily reduce triglycerides while increasing HDL-C, whereas ANGPTL3-targeted therapies offer broader lipid modulation, including substantial reductions in LDL-C. Both therapies demonstrate favorable safety profiles.
Gao et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: